加载中
Lycia Therapeutics, Inc. operates as a clinical-stage biotechnology company. It engages in the discovery and development of novel therapeutics designed to degrade disease-causing extracellular proteins, with an initial focus on addressing autoimmune, inflammatory, and allergic diseases. The company was founded in 2019 and is headquartered in South San Francisco, CA.
前收盘价
US$30.00
+US$12.00 · +66.67%
盘中时间采用ET。市场数据可能有所延迟。
Lycia Therapeutics, Inc. operates as a clinical-stage biotechnology company. It engages in the discovery and development of novel therapeutics designed to degrade disease-causing extracellular proteins, with an initial focus on addressing autoimmune, inflammatory, and allergic diseases. The company was founded in 2019 and is headquartered in South San Francisco, CA.
日内区间
当前US$30.00
52周区间
当前US$30.00
盘中时间采用ET。市场数据可能有所延迟。
Lycia Therapeutics, Inc. operates as a clinical-stage biotechnology company. It engages in the discovery and development of novel therapeutics designed to degrade disease-causing extracellular proteins, with an initial focus on addressing autoimmune, inflammatory, and allergic diseases. The company was founded in 2019 and is headquartered in South San Francisco, CA.
日内区间
当前US$30.00
52周区间
当前US$30.00
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
